Trends in reporting histological subtyping of renal cell carcinoma: association with cancer center type

被引:26
|
作者
Gansler, Ted [1 ]
Fedewa, Stacey [1 ]
Amin, Mahul B. [2 ]
Lin, Chun Chieh [1 ]
Jemal, Ahmedin [1 ]
机构
[1] Amer Canc Soc, Intramural Res, Atlanta, GA 30303 USA
[2] Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN 38163 USA
关键词
Renal cell carcinoma; Pathology; Classification; Registries; Healthcare quality; INTERNATIONAL-SOCIETY; PRACTICES RECOMMENDATIONS; CLASSIFICATION; IMMUNOHISTOCHEMISTRY; SURVIVAL; DATABASE; SYSTEM; IMPACT; TUMORS;
D O I
10.1016/j.humpath.2018.01.010
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Histological classification of renal cell carcinoma (RCC) has become increasingly important for clinical management. We identified 295 483 RCC diagnosed from 1998-2014 in the National Cancer Database (NCDB) to examine temporal trends in proportions of RCC with unspecified histology and several specific histologies from the 1998 and 2004 World Health Organization classifications of RCC. Further, multivariable log binomial analysis of 101 062 RCC diagnosed from 2010 to 2014 was used to determine whether the association of diagnosing/treating facility type and the proportion of unspecified RCC is independent of patient demographic and clinical factors. Between 1998 and 2014, the proportion of histologically unspecified RCC decreased substantially in all facility types, with the decrease smallest in community programs (from 86.0% to 28.1%) and largest in National Cancer Institute designated centers (from 85.1% to 9.8%). These decreases were offset by increases in percentages of papillary, clear cell, and chromophobe RCC cases. During 2010 to 2014, relative to community programs, RCCs were 21% less likely to be reported as unspecified histology (adjusted prevalence ratio [aPR] = 0.79; 95% CI, 0.68-0.92) in comprehensive community programs, 32% less likely in integrated network programs (aPR = 0.68; 95% CI, 0.57-0.92) and academic programs (aPR = 0.68; 95% CI, 0.54-0.87), and 63% less likely (aPR = 0.37; 95% CI, 0.26-0.52) in National Cancer Institute designated programs. These results have implications for the optimal selection of targeted systemic therapies for patients with advanced disease, and for the potential value of cancer registry data in pathology quality improvement programs to promote more rapid and consistent adoption of new classifications of RCC and other neoplasms. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:99 / 108
页数:10
相关论文
共 50 条
  • [41] Studying the association between breast cancer and renal cell carcinoma
    Khalid Jazieh
    Firas Baidoun
    Nataly Torrejon
    Zahi Merjaneh
    Anas Saad
    Mohamed Gad
    Amal Farouk
    Moshe Ornstein
    Jame Abraham
    Breast Cancer Research and Treatment, 2022, 191 : 643 - 652
  • [42] Renal cell neoplasm of oncocytosis: a type of unclassified renal cell carcinoma
    Masatake Shinohara
    Shoji Samma
    Yoshihiro Matsumoto
    Yoriaki Kagebayashi
    Yasushi Nakai
    Kazumasa Torimoto
    Keiji Shimada
    CEN Case Reports, 2014, 3 (1) : 10 - 13
  • [43] The effect of renal function change on renal cell carcinoma patients with tumor thrombus after nephrectomy and thrombectomy: a large Chinese center experience
    Liu, Zhuo
    Tang, Shiying
    Tian, Xiaojun
    Zhang, Hongxian
    Wang, Guoliang
    Zhang, Shudong
    Ma, Lulin
    BMC CANCER, 2020, 20 (01)
  • [44] Smooth Muscle Metaplasia in Renal Cell Carcinoma: A Specific Histological Entity or an Aspecific Stromal Reaction?
    Filosa, Alessandra
    Fabiani, Andrea
    ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY, 2012, 34 (06): : 334 - 336
  • [45] Update on the different histological types of renal cell carcinoma and their specific treatment
    Neuzillet, Y.
    PROGRES EN UROLOGIE, 2011, 21 : S23 - S26
  • [46] Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group
    Abreu, Diego
    Carvalhal, Gustavo
    Gueglio, Guillermo
    Tobia, Ignacio
    Garcia, Patricio
    Zuniga, Alvaro
    Meza, Luis
    Bengio, Ruben
    Scorticati, Carlos
    Castillejos, Ricardo
    Rodriguez, Francisco
    Maria Autran, Ana
    Gonzales, Carmen
    Gadu, Jose
    Nolazco, Alejandro
    Ameri, Carlos
    Zampolli, Hamilton
    Langenhin, Raul
    Muguruza, Diego
    Machado, Marcos Tobias
    Mingote, Pablo
    Yandian, Juan
    Clavijo, Jorge
    Nogueira, Lucas
    Clark, Omar
    Secin, Fernando
    Rovegno, Agustin
    Vilas, Ana
    Barrios, Enrique
    Decia, Ricardo
    Guimaraes, Gustavo
    Glina, Sidney
    Pal, Sumanta K.
    Rodriguez, Oscar
    Palou, Joan
    Spiess, Philippe
    Lara, Primo N. Jr Jr
    Linehan, W. Marston
    Pastore, Antonio Luigi
    Zequi, Stenio C.
    JCO GLOBAL ONCOLOGY, 2021, 7 : 671 - 685
  • [47] Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy
    Lisha Wang
    Sean R Williamson
    Mingsheng Wang
    Darrell D Davidson
    Shaobo Zhang
    Lee Ann Baldridge
    Xiang Du
    Liang Cheng
    Molecular Cancer, 13
  • [48] Succinate dehydrogenase deficient renal cell carcinoma: A case report of an uncommon renal cancer
    Kodare, Duhita
    Menon, Santosh
    Prakash, Gagan
    Desai, Sangeeta
    INDIAN JOURNAL OF CANCER, 2023, 60 (04) : 583 - 585
  • [49] Modified cancer TNM classification for localized renal cell carcinoma based on the prognostic analysis of 3748 cases from a single center
    Zhang, Jian
    Li, Xiaoli
    Lin, Jun
    Liu, Zhijia
    Tian, Ye
    Wang, Qiang
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2022, 100 (01) : 5 - 11
  • [50] Presence and extent of histological tumour necrosis is an adverse prognostic factor in papillary type 1 but not in papillary type 2 renal cell carcinoma
    Pichler, Martin
    Hutterer, Georg C.
    Chromecki, Thomas F.
    Pummer, Karl
    Mannweiler, Sebastian
    Zigeuner, Richard
    HISTOPATHOLOGY, 2013, 62 (02) : 219 - 228